Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$3.91 USD
+0.07 (1.82%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.90 -0.01 (-0.26%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MYGN 3.91 +0.07(1.82%)
Will MYGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
Other News for MYGN
Myriad Genetics (MYGN) Secures $200 Million Loan Facility from OrbiMed
Myriad genetics announces new $200 million credit facility
Myriad Genetics Announces New $200 Million Credit Facility | MYGN Stock News
Myriad Genetics announces $200M credit facility